The Choroidal Neovascularization drugs in development market research report provides comprehensive information on the therapeutics under development for Choroidal Neovascularization, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Choroidal Neovascularization. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Choroidal Neovascularization and features dormant and discontinued products.
GlobalData tracks 36 drugs in development for Choroidal Neovascularization by 31 companies/universities/institutes. The top development phase for Choroidal Neovascularization is preclinical with 18 drugs in that stage. The Choroidal Neovascularization pipeline has 30 drugs in development by companies and six by universities/ institutes. Some of the companies in the Choroidal Neovascularization pipeline products market are: Avirmax, University of Melbourne and University of Utah.
The key targets in the Choroidal Neovascularization pipeline products market include Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA), Vascular Endothelial Growth Factor (VEGF) , and Vascular Endothelial Growth Factor Receptor 1 (Fms Like Tyrosine Kinase 1 or Tyrosine Protein Kinase Receptor FLT or Tyrosine Protein Kinase FRT or Vascular Permeability Factor Receptor or VEGFR1 or FLT1 or EC 2.7.10.1).
The key mechanisms of action in the Choroidal Neovascularization pipeline product include Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA) Inhibitor with eight drugs in Phase III. The Choroidal Neovascularization pipeline products include five routes of administration with the top ROA being Intravitreal and nine key molecule types in the Choroidal Neovascularization pipeline products market including Gene Therapy, and Small Molecule.
Choroidal Neovascularization overview
Choroidal neovascularization (CNV) involves the growth of new blood vessels that originate from the choroid, the pigmented vascular layer of tissue behind the retina. Symptoms include painless loss of vision, metamorphopsia, and color disturbances. Treatment includes anti-vascular endothelial growth factor (anti-VEGF) agents, laser photocoagulation, and photodynamic therapy.
For a complete picture of Choroidal Neovascularization’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
